Affiliation:
1. Department of Immunology and Infectious Diseases, Palo Alto Medical Foundation, California 94301, USA. ml.fga@forsythe.stanford.edu
Abstract
Rifapentine, a derivative of rifamycin, was examined for its in vitro and in vivo activities against the protozoan parasite Toxoplasma gondii. The drug inhibited the intracellular replication of parasites and was not cytotoxic for the host cells at inhibitory concentrations. Mice infected either intraperitoneally with tachyzoites of the RH strain or orally with tissue cysts of the C56 strain were protected against death by treatment with rifapentine. The degree of protection was similar to that induced by atovaquone and apparently higher than that induced by rifabutin. Rifapentine may be a useful drug for the treatment of toxoplasmosis in immunocompromised individuals.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference16 articles.
1. Pharmacokinetics of rifapentine, a new long lasting rifamycin, in the rat, the mouse, and the rabbit;Alessandro A.;J. Antibiot.,1984
2. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii;Araujo F. G.;Antimicrob. Agents Chemother.,1991
3. Recent advances in the search for new drugs for treatment of toxoplasmosis;Araujo F. G.;Int. J. Antimicrob. Agents,1992
4. Rifabutin is active in models of murine toxoplasmosis;Araujo F. G.;Antimicrob. Agents Chemother.,1994
5. Azythromycin, rifabutin, and rifapentine for treatment and prophylaxis of Mycobacterium avium complex in rats treated with cyclosporine;Brown S. T.;Antimicrob. Agents Chemother.,1993
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献